We Provide Solutions to Current Challenges in CAR-T Therapies

Some Challenges for CAR- T Therapy:

  • Low Safety: life-threatening side effect from cytokine release syndrome (CRS) and virus-related risks in immunogenicity and genotoxicity

  • Low Effective Cell Production: ~14% patients failed to receive treatment due to low CAR-T production and T cell exhaustion

  • Low Efficacy: ~20% recurrence mainly from antigen escape for the approved CAR-T products, Kymriah® and Yescarta®, and not effective for solid tumors due to lack of true tumor-specific antigens, high heterogeneity, & hostile tumor microenvironment (TME)

  • Cost: High manufacturing cost for viral-method CAR-T production

螢幕快照 2019-06-14 下午5.03.11.png